SEPTIN14: A Potential Drug Target and Biomarker (G346288)

Target Name: SEPTIN14

NCBI ID: G346288

SEPTIN14

SEPTIN14: A Potential Drug Target and Biomarker

SEPTIN14, also known as human papillomavirus 18 (HPV18), is a gene that encodes for a protein known as p16INK4a. p16INK4a is a key regulator of cell growth and division, and is involved in the development and maintenance of preneoplasmic cells, which can eventually develop into cancer. The high-throughput sequencing of the SEPTIN14 gene has identified a number of potential drug targets and biomarkers that may be relevant to the treatment of various diseases.

One potential drug target for SEPTIN14 is the inhibition of p16INK4a activity. p16INK4a has been shown to play a role in the development of various cancers, including breast, ovarian, and prostate cancers. Additionally, p16INK4a has been linked to the development of skin and nervous system cancers. inhibiting p16INK4a activity may be a promising strategy for the treatment of these cancers.

Another potential drug target for SEPTIN14 is the regulation of cell adhesion. p16INK4a is involved in the regulation of cell-cell adhesion and has been shown to play a role in the development of various diseases, including cancer. By inhibiting p16INK4a activity, researchers may be able to develop new treatments for diseases that are characterized by disrupted cell adhesion, such as cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential drug targets, SEPTIN14 is also a potential biomarker for several diseases. The high-throughput sequencing of the SEPTIN14 gene has identified a number of potential protein biomarkers that may be relevant to the diagnosis and treatment of various diseases. For example, SEPTIN14 has been shown to be involved in the development and progression of several diseases, including cancer. By detecting SEPTIN14 levels in tissue samples or fluids from patients, researchers may be able to develop new diagnostic tests for these diseases and inform clinical decisions.

SEPTIN14 has also been shown to be involved in the regulation of several cellular processes that are important for human health, including cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). These processes are important for the development and maintenance of tissues and organs, and may be relevant to the treatment of diseases that are characterized by the disruption of these processes, such as cancer.

In conclusion, SEPTIN14 is a gene that encodes for a protein that is involved in the development and maintenance of preneoplasmic cells, which can eventually develop into cancer. The high-throughput sequencing of the SEPTIN14 gene has identified a number of potential drug targets and biomarkers that may be relevant to the treatment of various diseases. Further research is needed to fully understand the role of SEPTIN14 in human health and to develop new treatments for the diseases associated with its dysfunction.

Protein Name: Septin 14

Functions: Filament-forming cytoskeletal GTPase (Probable). Involved in the migration of cortical neurons and the formation of neuron leading processes during embryonic development (By similarity). Plays a role in sperm head formation during spermiogenesis, potentially via facilitating localization of ACTN4 to cell filaments (PubMed:33228246)

The "SEPTIN14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEPTIN14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets